Cite

    Juan Pablo Frias et al.. “Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens.” Diabetes, obesity & metabolism, vol. 22, no. 6, 2020, pp. 938–946. http://access.bl.uk/ark:/81055/vdc_100103422650.0x00002c